Mn Services Vermogensbeheer B.V. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 553,000 shares of the medical equipment provider's stock after purchasing an additional 12,700 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Boston Scientific were worth $59,398,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. 1248 Management LLC bought a new position in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific in the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.
Analyst Ratings Changes
Several analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday. Barclays upped their price target on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. UBS Group upped their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Finally, Robert W. Baird raised their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average price target of $118.04.
Read Our Latest Stock Analysis on BSX
Insider Activity at Boston Scientific
In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by corporate insiders.
Boston Scientific Trading Down 1.2%
Shares of Boston Scientific stock traded down $1.20 during mid-day trading on Monday, hitting $96.63. The stock had a trading volume of 3,975,219 shares, compared to its average volume of 7,682,847. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average of $104.40 and a two-hundred day moving average of $102.10. The firm has a market cap of $143.18 billion, a P/E ratio of 57.59, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm posted $0.62 earnings per share. The company's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
